ME Therapeutics Holdings Inc.
METX
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.56% | -30.08% | -15.31% | 92.68% | 727.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.26% | -18.88% | 3.57% | 312.21% | 908.27% |
| Operating Income | 16.26% | 18.88% | -3.57% | -312.21% | -908.27% |
| Income Before Tax | 12.81% | 20.98% | 91.85% | -278.72% | -737.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.81% | 20.98% | 91.85% | -278.72% | -737.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.81% | 20.98% | 91.85% | -278.72% | -737.67% |
| EBIT | 16.26% | 18.88% | -3.57% | -312.21% | -908.27% |
| EBITDA | 16.55% | 18.91% | -3.57% | -312.21% | -908.27% |
| EPS Basic | 18.69% | 51.35% | 94.92% | 2.17% | -205.71% |
| Normalized Basic EPS | 19.40% | -103.68% | 94.90% | 3.45% | -204.55% |
| EPS Diluted | 18.69% | 60.00% | 94.89% | 0.00% | -205.71% |
| Normalized Diluted EPS | 19.40% | -103.68% | 94.90% | 3.45% | -204.55% |
| Average Basic Shares Outstanding | 6.91% | 61.24% | 60.55% | 287.75% | 177.57% |
| Average Diluted Shares Outstanding | 6.91% | 61.24% | 60.55% | 287.75% | 177.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
